Next Investors logo grey

Creso JV prepped to launch pot-flavoured beers in Canada, Europe


Published 18-APR-2018 10:18 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX:CPH) has today informed the market that CLV Frontier Brands Pty Ltd (CLV), its equal one-third joint venture with UK-based Baltic Beer Company Ltd and Canadian TSX Venture incorporated LGC Capital, is schedule to have its first beers and tonics on sale in Europe and Canada during the northern hemisphere summer.

CLV is developing a bespoke and unique range of beers and tonics at its newly-built facilities in Europe, and has progressed into the brew testing phase.

Further, the TSX Venture Exchange has conditionally accepted LGC Capital’s joint venture investment in CLV, subject to LGC filing standard documentation with the Exchange.

Dr. Miri Halperin Wernli, co-founder and CEO of CPH commented on today’s news: “We see CLV as an exciting business partnership that we believe can add significant sales revenues to Creso Pharma over the coming years. Full details of the beer and tonic ranges will be released when CLV debuts its products and branding at a world-wide product launch.

“Europe will be the initial focus for sales, as Europe is the home market for the Baltic Beer Company’s multi award winning Viru beer. The company also plans to launch in Canada this summer,” she said.

However, how much of the market CPH is able to corner is speculative at this stage and therefore investors shouldn’t act on this fact alone, but should take all publicly available information into account and seek professional financial advice.

The unique selling point for CLV’s beers is the fact they contain terpenes, which carry the flavour and aroma of cannabis, without carrying THC, CBD or any other cannabinoids. The terpenes are extracted from various plant sources, all of which are food-grade, 100% natural and non-genetically modified (GMO) ingredients.

The terpenes added to CLV’s beers is pure and considered very safe for human consumption when added to products for flavor, having met the criteria of FDA/FEMA GRAS (Generally Recognized as Safe). The terpenes are added to the beverages at the post-fermentation stage in much the same manner as hop extracts are added.

Promisingly, the three companies comprising CLV will bring considerable market reach when it comes to commercialisation strategies, boasting networks across several continents between the three companies.

CPH’s growing pipeline of news

CPH has been busy across several areas of its business in recent months with news spanning acquisitions, product development and release, new strategic partnerships and more. Earlier this month, it updated the market around its heads of agreement for its proposed acquisition of Colombian medical cannabis group, Kunna S.A.S., and its parent company, Kunna Canada.

The company revealed last month that it plans to enter into the sports and osteoarthritic market with its innovative CBD-based cannaDOL® product range, comprising both oral nutraceuticals and functional cosmetics, by joining forces with FRIKE Technologies, the largest independent Swiss manufacturing group.

In February, CPH announced the completion of its acquisition of emerging Nova Scotia-based medicinal cannabis producer, Mernova Medicinal Inc, and accompanying formal entry into Canada — making it the only Australian cannabis company with direct exposure to the world’s largest legal medical cannabis market.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.